(Q34272152)

1 August 2017

1 reference

title

Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? (English)

1 reference

adaptive radiation therapy

1 August 2017

main subject

0 references

1 reference

1 reference

Numico G

1

1 reference

1 August 2017

Russi E

series ordinal

2

1 reference

1 August 2017

Merlano M

series ordinal

3

1 reference

1 August 2017

publication date

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

32

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

213-226

1 reference

Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Non-pharmacological intervention for breathlessness in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Dyspnea in cancer patients: Etiology, resource utilization, and survival-Implications in a managed care world

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Quality of life during chemotherapy in non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Brachytherapy in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Toxicity, physical function and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomized trial (chemotherapy versus radiotherapy)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

A retrospective quality of life analysis using the Lung Cancer Symptom Scale in patients treated with palliative radiotherapy for advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Wor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Neodymium:YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Palliative radiotherapy for lung cancer: two versus five fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Temporary tracheobronchial stenting in malignant stenoses.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900222-1

7 January 2021

10.1016/S0169-5002(00)00222-1

Identifiers

DOI

1 reference

1 August 2017

1 reference